1MD Kuzminova N. V.
1Gribenyuk O. V.
1Romanova V. O.
1MD Osovska N. Y.
2MD Knyazkova I. I.

1Ukraine, Vinnitsa, Vinnitsa National Medial University named after M. Pyrogov, Department of Internal Medicine No1
2Ukraine, Kharkiv, Kharkiv National Medical University, Department of Clinical Pharmacology



Today, weight gain is considered to be not only an important factor in the development and progression of hypertension, but also in the development of nonalcoholic fatty liver disease. According to the results of the examination of 170 patients with stage II hypertension, optimal body weight was observed only in 30 patients (17.6%), overweight — in 37 patients (21.7%), first degree obesity — in 58 (34.1%), second degree obesity — in 45 patients (26.5%). Abdominal fat distribution type predominated in more than 80% of patients with hypertension. The signs of nonalcoholic fatty liver disease, such as steatosis, were registered in 109 (64.1%) patients, its incidence progressively increasing together with body weight gain (from 40.0 % of patients with an optimal body weight and 54.1% of patients with overweight to 65.5% of patients with the 1st degree obesity and up to 86.7% of the 2nd degree obesity patients (p<0.05 compared to patients with optimal weight and overweight). Thus, this study demonstrated overweight, 1st and 2nd degrees obesity, to occur in the vast majority of patients with stage II essential hypertension. The frequency of hepatic steatosis increased with the increase in body mass index.

hepatic steatosis, hypertension, optimal body weight, overweight, obesity.


1. Drapkina O.M., Popova I.R. The role of obesity in the progression of hypertension and nonalcoholic fatty liver disease. Ukrayinskiy medichniy chasopis. 2013; 2(94): 125-128.
2. Chiang C.H., Huang C.C., Chan W.L. et al. The severity of nonalcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem. 2010; 43(18): 1399-1404.

3. Skybchyk V. A., Voytovych M.O. Nonalcoholic fatty liver disease: modern diagnostics. Hepatolohiya. 2015; 1: 52-56.
4. Сauchy F., Fuks D., Le Bian A. Z., Belghiti J., Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery. The new scourges. World J Hepatol. 2014 May 27: 6(5): 306-314.
5. Zhuravlyova A.K., Bobronnikova L.R. Predictors of fibrozis in patients with combination of non-alcoholic fatty liver disease and type 2 diabetes. Endokrinologiya. 2014; 19(2): 134-140.
6. Alshaalan R., Aljiffry M., Al-Busafi S., Metrakos P. Hassanain M. Nonalcoholic Fatty Liver Disease: Nonsinvasive Methods of Diagnosing Hepatic Steatosis. Saudi J Gastroenterol. 2015 Mar-Apr; 21 (2): 64-70.

7. Andres-Blasco I., Herrero-Cervera A., Vinue A. et al. Hepatic lipase deficiency produses glucosе intolerance, inflammation and hepatic steatosis. J Endocrinol. 2015 Dec; 227(3): 179-191.
8. Poynard T., Ngo Y., Perazzo H. et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y). 2011 Jul; 7 (7): 445-454;

9. Chеng S., Wiklund P., Autio R. et al. Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-alcoholic Fatty Liver Disease. PLoS One. 2015 Oct; 10(10): e0138889.
10. Chumak A.A., Ovsyannikova L.M., Kubashko A.V., Sarkisova E.O. Features of the molecular mechanisms of nonalcoholic fatty liver disease progression. Ukrayins’kyy medychnyy chasopys. 2013; 6(98): 33-39.
11. Stepanov Yu.M. Hepatic steatosis and steatohepatitis — the inevitability of mixed origin. Hastroenterolohyya. 2014; 4(54): 136-142.
12. Pasiyeshvili L.M., Zheleznyakova N.M., Pasiyeshvili T.M. Nonalcoholic fatty liver disease and hypertension: pathogenetic factors of the formation and progression. Hastroenterolohiya. 2014; 2 (52): 46-49.